search returned 100 results for adalimumab, showing results 91 to 100
28 March 2025 - Ltr to PBAC re proposed changes to PBS listings for adalimumab for certain...
28 June 2024 - Ltr to PBAC re adalimumab for juvenile AS
28 June 2024 - Ltr to PBAC re adalimumab for JIA
6 May 2024 - Response from PBAC re: listing of adalimumab for immune-mediated
https://rheumatology.org.au/For-Members/My-Portal/ARA-Advocacy/External-Correspondence
completed except – Pharmacy issues re:
adalimumab biosimilars and supply of Humira as still pending... to review and upload
to ARA website once finalised.
9 Pharmacy issues re: adalimumab biosimilars
https://rheumatology.org.au/LinkClick.aspx?fileticket=i7VZuFvheI8%3d
of a paediatric rheumatology centre
Where the term 'biological agent' appears, it refers to adalimumab... of neutropaenia
Adalimumab
Etanercept
Tocilizumab
Abatacept
Anakinra (Systemic JIA only)
Rituximab (RhF
https://rheumatology.org.au/LinkClick.aspx?fileticket=IK0BAgKoGVQ%3d
the PBS
listing to paediatric rheumatic disease as detailed below.
• Adalimumab – extension of PBS....
• Anti-Tumour Necrosis Factor medications (ie adalimumab, etanercept) – extension of PBS
listing
https://rheumatology.org.au/LinkClick.aspx?fileticket=vAKojMxO6oc%3d
completed except – Pharmacy issues re:
adalimumab biosimilars and supply of Humira as still pending... to review and upload
to ARA website once finalised.
9 Pharmacy issues re: adalimumab biosimilars
https://rheumatology.org.au/LinkClick.aspx?fileticket=i7VZuFvheI8%3d&portalid=2
the PBS
listing to paediatric rheumatic disease as detailed below.
• Adalimumab – extension of PBS....
• Anti-Tumour Necrosis Factor medications (ie adalimumab, etanercept) – extension of PBS
listing
https://rheumatology.org.au/LinkClick.aspx?fileticket=vAKojMxO6oc%3d&portalid=2
of a paediatric rheumatology centre
Where the term 'biological agent' appears, it refers to adalimumab... of neutropaenia
Adalimumab
Etanercept
Tocilizumab
Abatacept
Anakinra (Systemic JIA only)
Rituximab (RhF
https://rheumatology.org.au/LinkClick.aspx?fileticket=IK0BAgKoGVQ%3d&portalid=2
was
undertaken prior to the widespread availability of adalimumab biosimilars and
encourage any... adalimumab listing as a HSD not general schedule listing
5. The APRG estimate that patients who receive adalimumab or etanercept on compassionate
grounds for non-PBS indications (uveitis or SaJIA
https://rheumatology.org.au/LinkClick.aspx?fileticket=%2fsNZqt238Qg%3d
was
undertaken prior to the widespread availability of adalimumab biosimilars and
encourage any... adalimumab listing as a HSD not general schedule listing
5. The APRG estimate that patients who receive adalimumab or etanercept on compassionate
grounds for non-PBS indications (uveitis or SaJIA
https://rheumatology.org.au/LinkClick.aspx?fileticket=_sNZqt238Qg%3d&portalid=2
also highlighted some recent positive PBAC recommendations, namely:
o new paediatric adalimumab... listing for adalimumab for severe active JIA (reduced
MTX dose 15mg/m
2
, changes to prescribing...
leaflets as due for review which were assigned as follows:
o Adalimumab - HC
o Biosimilars - WR
o
https://rheumatology.org.au/LinkClick.aspx?fileticket=4kWy17O9iqY%3d